Inside informationEnglish
Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Sanofi
- Filed
- 18/05/2026, 21:30
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 112638_20260518